Ginkgo Bioworks Holdings, Inc.
Here’s whether Ginkgo Bioworks Holdings, Inc. (DNA) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Caution.
Positives: above the 50-day MA (medium-term momentum positive); strong 1-year return of +39.4%; 3-month momentum positive (+5.9%). Concerns: trading below the 200-day MA (long-term downtrend); 50-day MA is falling (-3.01% over 10 days); RSI 78 — overbought, elevated pullback risk. Currently 44.8% off its 52-week high. Score: -1/7.
DNA is trading below its 200-day MA ($10.05) — a key warning sign the longer-term trend is under pressure. With an RSI of 78.0, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of +39.4% compares to +27.9% for SPY (beat the market by 11.5%). The current 44.8% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.